Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake

Assessment of treatment response in cardiac sarcoidosis based on myocardial 18F-FDG uptake

ObjectiveImmunosuppressive therapy for cardiac sarcoidosis (CS) still largely consists of corticosteroid monotherapy. However, high relapse rates after tapering and insufficient efficacy are significant problems. The objective of this study was to investigate the efficacy and safety of non-biologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukas Frischknecht, Jan Schaab, Eloi Schmauch, Ayla Yalamanoglu, Dennis D. Arnold, Judith Schwaiger, Christiane Gruner, Ronny R. Buechel, Daniel P. Franzen, Antonios G.A. Kolios, Jakob Nilsson
Formato: Artículo
Lenguaje:English
Publicado: Frontiers Media S.A. 2023-11-01
Colección:Frontiers in Immunology
Materias:
cardiac sarcoidosis
myocardial 18F-FDG PET
Anti-TNF
adalimumab
azathioprin
SUVmax
Acceso en línea:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286684/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1286684/full

Ejemplares similares